Clementia
IPO
- Headquarters
- Montreal
- Employees
- 11–50
- Founded
- 2013
- Business Model
- B2B
- Website
- clementiapharma.com
- Total Funding
- $92.5M
- Last Round
- $60.0M Venture RoundJun 2015
About
Clementia Pharmaceuticals was a Montreal-based rare disease biopharmaceutical company founded in 2011. Its lead compound palovarotene, a retinoic acid receptor gamma agonist, was in clinical development for fibrodysplasia ossificans progressiva and multiple osteochondromas. Clementia was acquired by Ipsen in 2019 for approximately $1.3 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account